5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)Inhye E. Ahn, Matthew S. Davids, Svitlana Tyekucheva et al.|Hematological Oncology|2023Cited by 1
73 | PRIMARY ENDPOINT EVALUATION OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH R‐CHOP (VR‐CHOP) FOR PATIENTS WITH RICHTER SYNDROMEMatthew S. Davids, Kathleen A. Rogers, Christine E. Ryan et al.|Hematological Oncology|2025Cited by 0